What does Pharma2Care do?

Pharma2Care is a pharmacy in Zuienkerke. Public Limited, started on 29 May 1985, 1 establishment.

What is the address of Pharma2Care?

The registered office of Pharma2Care is located at Nieuwe Steenweg 50, 8377 Zuienkerke.

Is Pharma2Care still active?

Yes. According to the CBE (29 October 2026) Pharma2Care is active, legal situation “Normale toestand”, started on 29 May 1985.

Is Pharma2Care registered on Peppol?

Yes, Pharma2Care is registered on the Peppol network with ID 0208:0427391896.

What is the enterprise number of Pharma2Care?

The enterprise number of Pharma2Care is BE0427391896.

When was Pharma2Care founded?

Pharma2Care was founded on 29 May 1985.

Who are the directors of Pharma2Care?

According to the 2024 annual accounts, the directors of Pharma2Care are: Pharma Force NV.

Is Pharma2Care a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 May 1985; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did Pharma2Care make in 2024?

Pharma2Care recorded a loss after taxes of € 92,638 in financial year 2024.

What is the revenue of Pharma2Care?

As a small company, Pharma2Care is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € -9,779.

How much does an employee at Pharma2Care earn?

The average wage cost per full-time employee at Pharma2Care was € 12,900 in 2023: staff costs of € 40,003 for 3.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

Pharma2Care (Public Limited) - Zuienkerke - BE0427391896

Dossier Pharma2Care, printed on 29 October 2026 from databakkes.be/en/0427391896/pharma2care. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2023 and 2024.

Financials

Financial year 2024

Pharma2Care from Zuienkerke, company number BE0427391896, closed financial year 2024 with a result of € -92,638 after tax. For that financial year Pharma2Care recorded a gross margin of € -9,779 and equity of € 1 million. Compared with financial year 2023, the result moved from € -61,337 to € -92,638. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2025.

What it is worth Healthy

€ 1 million

▼ 8% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -92,638

▼ 51 % more loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 1,168

▼ 90% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -257,904.

Debts at end 2024

Bank debt

€ 749,456

▲ 72% vs 2023

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 39,690

▼ 34% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 920,742 Gross margin 2021: € 920,742 First fiscal year in the series	€ 695,777 Gross margin 2022: € 695,777 ▼ 24% vs 2021 (€ 920,742) Unfavourable step	€ 160,783 Gross margin 2023: € 160,783 ▼ 77% vs 2022 (€ 695,777) Unfavourable step	€ -9,779 Gross margin 2024: € -9,779 ▼ € 170,562 vs 2023 (€ 160,783) Unfavourable step	▼ € 170,562
Profit after taxes	€ 246,254 Profit after taxes 2021: € 246,254 First fiscal year in the series	€ 58,590 Profit after taxes 2022: € 58,590 ▼ 76% vs 2021 (€ 246,254) Unfavourable step	€ -61,337 Profit after taxes 2023: € -61,337 ▼ € 119,927 vs 2022 (€ 58,590) Unfavourable step	€ -92,638 Profit after taxes 2024: € -92,638 ▼ € 31,301 vs 2023 (€ -61,337) Unfavourable step	▼ € 31,301
Equity	€ 1,135,725 Equity 2021: € 1,135,725 First fiscal year in the series	€ 1,194,315 Equity 2022: € 1,194,315 ▲ 5% vs 2021 (€ 1,135,725) Favourable step	€ 1,132,978 Equity 2023: € 1,132,978 ▼ 5% vs 2022 (€ 1,194,315) Unfavourable step	€ 1,040,340 Equity 2024: € 1,040,340 ▼ 8% vs 2023 (€ 1,132,978) Unfavourable step	▼ 8%
Total debts	€ 1,419,854 Total debts 2021: € 1,419,854 First fiscal year in the series	€ 1,394,105 Total debts 2022: € 1,394,105 ▼ 2% vs 2021 (€ 1,419,854) Favourable step	€ 502,966 Total debts 2023: € 502,966 ▼ 64% vs 2022 (€ 1,394,105) Favourable step	€ 971,563 Total debts 2024: € 971,563 ▲ 93% vs 2023 (€ 502,966) Unfavourable step	▲ 93%
Cash	€ 29,266 Cash 2021: € 29,266 First fiscal year in the series	€ 60,846 Cash 2022: € 60,846 ▲ 108% vs 2021 (€ 29,266) Favourable step	€ 11,599 Cash 2023: € 11,599 ▼ 81% vs 2022 (€ 60,846) Unfavourable step	€ 1,168 Cash 2024: € 1,168 ▼ 90% vs 2023 (€ 11,599) Unfavourable step	▼ 90%
Land & buildings	€ 184,488 Land & buildings 2021: € 184,488 First fiscal year in the series	€ 177,724 Land & buildings 2022: € 177,724 ▼ 4% vs 2021 (€ 184,488) Unchanged	€ 139,369 Land & buildings 2023: € 139,369 ▼ 22% vs 2022 (€ 177,724) Unchanged	€ 98,821 Land & buildings 2024: € 98,821 ▼ 29% vs 2023 (€ 139,369) Unchanged	▼ 29%
Retained profit	€ -162,519 Retained profit 2021: € -162,519 First fiscal year in the series	€ -103,929 Retained profit 2022: € -103,929 ▲ € 58,590 vs 2021 (€ -162,519) Favourable step	€ -165,266 Retained profit 2023: € -165,266 ▼ € 61,337 vs 2022 (€ -103,929) Unfavourable step	€ -257,904 Retained profit 2024: € -257,904 ▼ € 92,638 vs 2023 (€ -165,266) Unfavourable step	▼ € 92,638
Bank debt	€ 265,015 Bank debt 2021: € 265,015 First fiscal year in the series	€ 209,446 Bank debt 2022: € 209,446 ▼ 21% vs 2021 (€ 265,015) Favourable step	€ 435,427 Bank debt 2023: € 435,427 ▲ 108% vs 2022 (€ 209,446) Unfavourable step	€ 749,456 Bank debt 2024: € 749,456 ▲ 72% vs 2023 (€ 435,427) Unfavourable step	▲ 72%
Balance sheet total	€ 2,555,579 Balance sheet total 2021: € 2,555,579 First fiscal year in the series	€ 2,588,420 Balance sheet total 2022: € 2,588,420 ▲ 1% vs 2021 (€ 2,555,579) Unchanged	€ 1,635,944 Balance sheet total 2023: € 1,635,944 ▼ 37% vs 2022 (€ 2,588,420) Unchanged	€ 2,011,903 Balance sheet total 2024: € 2,011,903 ▲ 23% vs 2023 (€ 1,635,944) Unchanged	▲ 23%
Employees (FTE)	12.8 Employees (FTE) 2021: 12.8 First fiscal year in the series	9.3 Employees (FTE) 2022: 9.3 ▼ 3.5 vs 2021 (12.8) Unchanged	3.1 Employees (FTE) 2023: 3.1 ▼ 6.2 vs 2022 (9.3) Unchanged	-

Key figures of Pharma2Care, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to Pharma2Care?

What happened at Pharma2Care in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 23, 2025 New annual accounts for financial year 2024: loss of € 92,638. Source: NBB ↗
2018 Pharma Force NV became a director. NBB
Jul 2, 1985 New establishment in Zuienkerke. KBO
May 29, 1985 Start of the company according to the CBE. KBO

In short

From € 246,254 profit in 2021 to € 92,638 loss in 2024.

Best year ever: 2021, with € 246,254 profit.

On average € 51,900 of value added per employee in 2023.

Original PDFs at the National Bank ↗

Management

peeters mathieu management 100%

The stake of peeters mathieu management comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Pharma2Care

Behind Pharma2Care is Pharma Force NV. The shares are held by peeters mathieu management (100%).

Directors

According to the 2024 annual accounts

Pharma Force NV

Director · represented by Mathieu Peeters

Also active at: PHARMA BASE, ZELLIK PHARMA

since 2018

Shareholders

peeters mathieu management

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Nieuwe Steenweg 50

8377 Zuienkerke

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

DGVS

€ 772,136 gross margin · 2025

Savels-VDB

€ 487,799 gross margin · 2025

VSV DEVELOPMENT

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0427.391.896

VAT number

BE 0427.391.896

Registered office

Nieuwe Steenweg 50, 8377 Zuienkerke

Names & denominations

Pharma2Care

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

29 May 1985

Peppol

Active · Active since 17 Jul 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Pharma2Care

Warning lights

Financials

What happened to Pharma2Care?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions